SEC Form 25-NSE filed by IVERIC bio Inc.

7/11/23 10:24:16 AM ET

$ISEE

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ISEE alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36080

Issuer:	IVERIC bio, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	One Penn Plaza, 19th Floor
	New York	NEW YORK	10119
Telephone number:				212-845-8200

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2023-07-11	By	Tara Petta		Director
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ISEE alert in real time by email

Recent Analyst Ratings for

$ISEE

Date	Price Target	Rating	Analyst
5/1/2023		Buy → Neutral	Guggenheim
11/10/2022	$30.00 → $20.00	Buy → Hold	Jefferies
10/17/2022		Sell → Neutral	B. Riley Securities
9/6/2022	$12.00 → $8.00	Neutral → Sell	B. Riley Securities
8/2/2022	$20.00	Buy	UBS
6/8/2022	$30.00	Buy	Guggenheim
6/8/2022	$18.00	Buy	BofA Securities
5/12/2022	$12.00	Neutral	B. Riley Securities

More analyst ratings

SEC Form 25-NSE filed by IVERIC bio Inc.

Chat with this insight

Recent Analyst Ratings for
$ISEE

$ISEE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

SEC Form SC 13G/A filed by IVERIC bio Inc. (Amendment)

$ISEE
SEC Filings

SEC Form 15-12G filed by IVERIC bio Inc.

SEC Form EFFECT filed by IVERIC bio Inc.